^
Association details:
| Biomarker: | SMARCB1 mutation |
|---|---|
| Cancer: | Breast Cancer |
| Drug Class: | FGFR inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Molecular profiling of metastatic breast cancer (MBC) and target-based therapeutic matching in an Asian tertiary phase I oncology unit.
Published date:
05/13/2020
Excerpt:
Pts with MBC referred to a phase I unit underwent NGS (n = 152)….1 pt with SMARCB mutation, reportedly associated with the FGFR pathway, had a PFS of 70w on tx with a pan-FGFR inhibitor after progressing on 3 prior lines of tx (ET and CT).
DOI:
10.1200/JCO.2020.38.15_suppl.3561
